Nerivio is a wearable device that treats migraine by sending mild electrical pulses through your upper arm, triggering your brain’s built-in pain suppression system. It’s FDA-cleared for both acute and preventive migraine treatment in anyone 12 or older, and it works without medication. The concept is straightforward: a carefully calibrated signal in one part of your body tells your brain to dial down pain signals coming from another part, in this case your head.
The Pain Modulation Pathway
Nerivio uses a technique called remote electrical neuromodulation, or REN. The device stimulates pain-sensing nerve fibers in your upper arm at a level that’s strong enough to activate those fibers but stays below your actual pain threshold. You feel the sensation clearly, but it doesn’t hurt. That distinction is the key to how the whole system works.
Those activated nerve fibers send signals up through your spinal cord to your brainstem, where your body’s pain regulation centers sit. Once those centers detect the incoming signal, they trigger what’s known as conditioned pain modulation, a natural mechanism where a stimulus in one area of the body suppresses pain in a distant area. Think of it as your brain’s built-in volume knob for pain. The brainstem responds by releasing serotonin and noradrenaline, two chemical messengers that travel back down and block the migraine pain signals before they fully register. Specifically, these chemicals inhibit incoming pain messages at the point where head and neck pain signals converge on their way to the brain.
Brain imaging studies in healthy volunteers have confirmed that this process produces measurable changes in brainstem activity, and the strength of those changes correlates with how much pain relief a person experiences. In other words, the harder the brainstem responds, the more effective the treatment tends to be.
Where You Wear It and How Long
The device wraps around the lateral (outer) part of your upper arm. You control it through a smartphone app, which lets you start a session and adjust the stimulation intensity using simple plus and minus buttons. Every treatment lasts 45 minutes.
The recommended approach is to set the intensity so it feels strong and clearly noticeable but not painful. That “just below the pain threshold” sweet spot is where the nerve activation is optimized. Starting too low may not generate enough signal to trigger the brainstem response, while going above the pain threshold isn’t necessary and defeats the purpose of keeping the stimulus sub-painful. Most people find their ideal level within the first few sessions.
Acute Treatment vs. Prevention
Nerivio has two distinct modes of use. For acute treatment, you apply the device at the onset of a migraine headache or aura and run a single 45-minute session. The goal is to reduce or eliminate the pain of that specific attack. For preventive use, you run a 45-minute session every other day regardless of whether you have a migraine, training your pain modulation system to stay more active over time.
The FDA initially cleared Nerivio for acute migraine treatment in 2019. In February 2023, the clearance expanded to include preventive treatment of migraine with or without aura in patients 12 and older. This makes it one of the few non-drug options approved for both purposes in adolescents and adults.
How Well It Works
In a study of people with chronic migraine (15 or more headache days per month), 59.3% achieved pain relief at the two-hour mark after treatment, and 20.9% were completely pain-free. For context, the estimated sham (placebo) response rate from previous studies was about 39%, giving Nerivio a therapeutic gain of roughly 20 percentage points, a statistically significant difference. These numbers come from an open-label study, meaning participants knew they were using the real device, so some placebo effect is built into the overall numbers. Still, that 20-point gap over sham holds up as a meaningful clinical benefit.
A separate randomized, double-blind, placebo-controlled trial confirmed that REN provides significantly greater pain relief than a sham device, reinforcing that the effect isn’t purely psychological.
Who Should Not Use It
Nerivio is not appropriate for everyone. The FDA lists several groups who should avoid the device:
- People with active implanted medical devices such as pacemakers, cochlear implants, or any other implanted electronic device. The electrical stimulation could cause interference, shock, or serious injury.
- People with severe cardiac or cerebrovascular disease, including congestive heart failure.
- People with uncontrolled epilepsy.
If you have any implanted electronic device, this is a hard contraindication, not a judgment call. The electrical signals from Nerivio can directly interfere with those devices.
Getting a Prescription and Paying for It
Nerivio requires a prescription. Your doctor or neurologist writes the prescription, and the device is shipped to you for home use. However, insurance coverage remains a significant barrier. Many major insurers, including the Federal Employees Program (FEP Blue), classify remote electrical neuromodulation as “not medically necessary” and treat it as experimental. There is no national Medicare coverage determination either, so coverage depends on individual carriers and regional decisions.
In practice, this means many patients pay out of pocket. Theranica, the company behind Nerivio, sells the device on a subscription basis, and pricing can vary. If your insurance denies coverage, it may be worth asking your provider about an appeal, since the expanded FDA clearance and growing clinical evidence can sometimes support reconsideration.